{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-135263","form_type":"8-K","ticker":null,"cik":"0001828522","company_name":"eFFECTOR Therapeutics, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.465480+00:00","generated_at":"2026-06-02T06:56:06.596328+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"eFFECTOR Q1 net loss $8.8M; tomivosertib NSCLC fails; zotatifin advance","bullets":["Net loss of $8.8M ($2.16 per share) vs $10.0M ($5.96 per share) in Q1 2023.","Cash, equivalents, and short-term investments $25.4M at March 31, 2024; raised $15M in Jan 2024 registered direct offering.","Zotatifin ZFA triplet dose escalation at 0.14 mg/kg; RP2D expected H2 2024.","Tomivosertib KICKSTART trial in NSCLC: HR 0.62 (p=0.21), missed pre-specified 0.2 threshold; no path forward.","R&D expense decreased to $5.3M from $6.6M; cash runway into Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-135263","json":"https://secwatch.observer/filing/0001193125-24-135263.json","markdown":"https://secwatch.observer/filing/0001193125-24-135263.md","text":"https://secwatch.observer/filing/0001193125-24-135263.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828522/000119312524135263/0001193125-24-135263-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828522/000119312524135263/d822499d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:56:06.596328+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4a3f42729bbe4ce11ab252bad378ec28f447387c","claim":"eFFECTOR Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2024.","evidence_excerpt":"On May 9, 2024, eFFECTOR Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828522/000119312524135263/0001193125-24-135263-index.htm","confidence":0.75,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}